anagenesis biotechnologies logo

Anagenesis Biotechnologies SAS.

Anagenesis Biotechnologies is a preclinical?stage stem cell-based company focused on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs.

The company was cofounded by Pr. Olivier Pourqui_, Professor at Harvard Medical School and the Brigham and Womans Hospital and a member of the Harvard Stem Cell Institute.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://anagenesis-biotech.com
Founded2011
Disease Focus
Development StagePreclinical
STOCK CODENon Listed
Address
650 Boulevard Gonthier dAndernach67400, Graffenstaden
Illkirch
France
Email
Contact Number
+33 3 88 43 10 08

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/anagenesis-biotechnologies” connections=”true” suffix=””]

Anagenesis have a unique proprietary technology to regenerate muscle cells (satellite cell) from stem cells, which allows the company to generate unlimited quantities of Paraxial Mesoderm Multipotent Cells (P2MCs) and differentiated muscle cells by in vitro successfully recapitulating each step of the embryonic and foetal myogenesis.

May 2017, Anagenesis sign research agreement with Boehringer Ingelheim to support Boehringer Ingelheim R&D efforts in the discovery of treatments for chronic musculoskeletal diseases such as sarcopenia and cachexia.

June 2016, Anagenesis sign strategic in -licensing and collaborate agreement with CRISPR Therapeutics to develop CRISPR/Cas9 – based Cell Therapies for Muscle Diseases, which grants CRISPR Therapeutics exclusive worldwide license to Anagenesis proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology for cell therapy for all human muscle diseases.

In Dec 2013, Anagenesis Biotechnologies signs an exclusive worldwide license agreement with INSERM Transfert and AFM on two patent families protecting the P2MC production technology.

In April 2015, Anagenesis secures its second private investment with CAP INNOVEST. In Dec 2013, it secured its first private funding from AFM (French muscular dystrophy association).